Amedeo's Top 20

Amedeo Smart

Independent Medical Education

31 July 2023

Multidisciplinary Journal Club

  1. Asadi-Pooya AA, Brigo F, Lattanzi S, Blumcke I, et al.
    Adult epilepsy.
    Lancet 2023.

  1. Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, et al.
    Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
    N Engl J Med 2023;389:205-214.

  2. Singh N, Daly ME, Ismaila N.
    Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol 2023.

  3. Sperling RA, Donohue MC, Raman R, Rafii MS, et al.
    Trial of Solanezumab in Preclinical Alzheimer's Disease.
    N Engl J Med 2023.

  4. Tsuboi M, Herbst RS, John T, Kato T, et al.
    Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
    N Engl J Med 2023.

  1. Puledda F, Dipasquale O, Gooddy BJ, Karsan N, et al.
    Abnormal glutamatergic and serotonergic connectivity in visual snow syndrome and migraine with aura.
    Ann Neurol 2023.

  2. Cabrera Lopez C, Sanchez Santos A, Lemes Castellano A, Cazorla Rivero S, et al.
    Eosinophils Sub-Types in Asthmatic and COPD Patients.
    Am J Respir Crit Care Med 2023.

  3. Sims JR, Zimmer JA, Evans CD, Lu M, et al.
    Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    JAMA 2023.

  4. Virani SS, Newby LK, Arnold SV, Bittner V, et al.
    2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
    Circulation 2023.

  5. Desai AS, Webb DJ, Taubel J, Casey S, et al.
    Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
    N Engl J Med 2023;389:228-238.

  1. Khurshid S, Al-Alusi MA, Churchill TW, Guseh JS, et al.
    Accelerometer-Derived "Weekend Warrior" Physical Activity and Incident Cardiovascular Disease.
    JAMA 2023;330:247-252.

  2. Kjaer MN, Meyhoff TS, Sivapalan P, Granholm A, et al.
    Long-term effects of restriction of intravenous fluid in adult ICU patients with septic shock.
    Intensive Care Med 2023;49:820-830.

  3. Ronot M, Nahon P, Rimola J.
    Screening of liver cancer with abbreviated MRI.
    Hepatology 2023;78:670-686.

  4. Tian T, Qi Z, Huang S, Wang H, et al.
    Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.
    J Clin Endocrinol Metab 2023;108:2033-2041.

  5. Augusto DG, Murdolo LD, Chatzileontiadou DSM, Sabatino JJ Jr, et al.
    A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection.
    Nature 2023.

  1. Al-Jabri R, Afif W.
    In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.
    Ann Intern Med 2023;176:JC82.

  2. Suleman A, Aktar SJ, Ante Z, Liu N, et al.
    Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
    Br J Haematol 2023.

  3. Wilde AAM, Amin AS, Morita H, Tadros R, et al.
    Use, misuse, and pitfalls of the drug challenge test in the diagnosis of the Brugada syndrome.
    Eur Heart J 2023;44:2427-2439.

  4. Gelfand AA, Allen IE, Grimes B, Irwin S, et al.
    Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.
    Headache 2023.

  5. Wesner K, Hiemke C, Bergemann N, Egberts KM, et al.
    Therapeutic Reference Range for Olanzapine in Schizophrenia: Systematic Review on Blood Concentrations, Clinical Effects, and Dopamine Receptor Occupancy.
    J Clin Psychiatry 2023;84.


more..

Privacy Policy